Physician profile
Emily Silverman
NPI 1346695467
$6,974.18
in general payments reported to CMS, 2019-2025
38 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.66 · 2021: $427 · 2022: $1,729 · 2023: $1,831 · 2024: $812 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,804.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,315.13 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Dexcom, INC. | $989.06 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Novo Nordisk INC | $754.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $419.40 | 2021-2023 | Farxiga |
| Insulet Corporation | $374.77 | 2023-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $372.27 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $371.77 | 2022-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $352.54 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $322.40 | 2022-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $271.20 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $228.35 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $208.31 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $136.89 | 2021-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $100.38 | 2024-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.84 | 2024-2025 | Jardiance |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $74.57 | 2022-2024 | Cequr Simplicity |
| Ibsa Pharma INC. | $59.82 | 2022-2025 | Licart, Tirosint, Tirosint |
| Ascendis Pharma Endocrinology INC | $55.39 | 2025 | Yorvipath |
| Mannkind Corporation | $52.83 | 2021-2025 | |
| Madrigal Pharmaceuticals | $39.65 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $33.68 | 2023-2025 | Contrave |
| Amphastar Pharmaceuticals, INC. | $30.92 | 2025 | |
| Merck Sharp & Dohme LLC | $30.89 | 2022-2025 | Capvaxive, Gardasil 9 |
| Embecta Corp. | $30.19 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Horizon Therapeutics Plc | $26.69 | 2023 | Tepezza |
| Amarin Pharma, INC. | $25.70 | 2021-2022 | |
| Glaxosmithkline, LLC. | $25.38 | 2022-2023 | Trelegy Ellipta |
| Alkermes, INC. | $25.21 | 2025 | Vivitrol |
| Ultragenyx Pharmaceutical INC. | $19.56 | 2023 | |
| Ascensia Diabetes Care US INC. | $19.05 | 2025 | |
| Pfizer INC. | $18.83 | 2025 | |
| Averitas Pharma INC. | $18.00 | 2025 | Qutenza |
| Nevro Corp. | $16.01 | 2021 | |
| Amryt Pharma Holdings LTD | $14.17 | 2023 | Mycapssa |
| Abbvie INC. | $14.06 | 2023 | Synthroid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.66 | 2019 | |
| Vistapharm, INC. | $13.45 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.